Nindi Elfiza, Defriman Djafri, Ade Suzana Eka Putri
This article has been read 143 times.
This PDF has been read 37 times.


The rapid and uncontrolled transmission of COVID-19, causes the high morbidity and mortality rates of COVID-19 throughout the world, including West Sumatra (CFR 2.27%). This study aims to analyze the mortality of COVID-19 in West Sumatra and the risk factors that influence it. The research design retrospective cohort using secondary data on COVID-19 cases in West Sumatra from March 26, 2020 to June 7, 2021. The sampling technique is total sampling provided that the sample criteria are met. Data analysis used logistic regression method. 44,693 confirmed cases of COVID-19, 968 (2.17%) died and 43,725 (97.83%) did not die. Factors associated with COVID-19 mortality were age (RR 9.79; 95% CI 8.65-11.09), gender (RR 1.51; 95% CI 1.33-1.71), diabetes (RR 10.21; 95% CI 8.91-11.69), hypertension (RR 6.49; 95% CI 5.59-7.54), cardiovascular diseases (RR 9.57; 95% CI 8.17-11.21), COPD (RR 10.51; 95% CI 7.57-14.57), asthma (RR 2.03; 95% CI 1.23-3.34), and kidney diseases (RR 19.87; 95% CI 16.54-23.86). Kidney diseases are the most dominant factor associated with COVID-19 mortality (RR 16.07; 95% CI 11.34-22.78). COVID-19 patients with kidney disease have the highest risk of death. Treatment of patients with comorbidities must be prioritized and improve health promotion in at-risk groups.

Full Text:



Khan M, Khan H, Khan S, Nawaz M. Epidemiological and clinical characteristics of coronavirus disease (COVID-19) cases at a screening clinic during the early outbreak period: a single-centre study. Journal of Medical Microbiology. 2020;69:1114-1123.

Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314 Cases From the Chinese Center for Disease Control and Prevention. JAMA. 2020; published online February 24.

Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet. 2020; published online January 24.

Cucinotta D, Vanelli M. WHO Declares COVID-19 a Pandemic. Acta Biomed. 2020;91(1):157–160.

WHO Coronavirus (COVID-19) : 1 Juni 2021 2021 [Available from: https://covid19.who.int/.

Our World in Data, Statistics and Research Coronavirus Pandemic (COVID-19) : 8 Juli 2021 2021 [Available from: https://ourworldindata.org/coronavirus.

Muhamad SV. Pandemi COVID-19 sebagai Persoalan Serius Banyak Negara di Dunia. Pusat Penelitian Badan Keahlian DPR RI. 2021;8(13):7-12.

Dinas Komunikasi dan Informasi Provinsi Sumatera Barat. Data Pantauan COVID-19 Provinsi Sumatera Barat 2020 [Available from: https://corona.sumbarprov.go.id/.

Wang L, He W, Yu X, Hu D, Bao M, Liu H, et al. Coronavirus Disease 2019 in Elderly Patients: Characteristics and Prognostic Factors Based on 4-Week Follow-up. Journal of Infection. 2020;80(6):629-45.

Li X, Xu S, Yu M, Wang K, Tao Y, Zhou Y, et al. Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan. Journal of Allergy Clinical Immunology. 2020;146(1):110-118.

Santos MM, Lucena EES, Lima KC, Brito AAC, Bay MB, Bonfada D. Survival and predictors of deaths of patients hospitalized due to COVID-19 from a retrospective and multicenter cohort study in Brazil. Journal of Epidemiology and Infection. 2020;148(e198):1-11.

Satria RMA, Tutupoho RV, Chalidyanto D. Analisis Faktor Risiko Kematian dengan Penyakit Komorbid COVID-19. Jurnal Keperawatan Silampari. 2020;4(1):48-55.

Sousa GJB, Garces TS, Cestari VRF, Florencio RS, Moreira TMM, Pereira MLD. Mortality and survival of COVID-19. Journal of Epidemiology and Infection. 2020;148(e123):1-6.

Zandkarimi E, Moradi G, Mohsenpour B. The Prognostic Factors Affecting the Survival of Kurdistan Province COVID-19 Patients : A Cross-Sectional Study from February to May 2020. International Journal of Health Policy Management. 2020.

Salinas-Escudero G, Carillo-Vega MF, Granados-Garcia V, Martinez-Valverde S, Toledano-Toledano F, Garduno-Espinosa J. A survival analysis of COVID-19 in the Mexican Population. BMC Public Health. 2020;20(1):1-8.

Ng J, Bakrania K, Falkous C, Russels R. COVID-19 Mortality by Age, Gender, Ethnicity, Obesity, and Other Risk Factors A Comparison Against All-Cause Mortality. 2020.

Wang L, He W, Yu X, Hu D, Bao M, Liu H, et al. Coronavirus Disease 2019 in Elderly Patients: Characteristics and Prognostic Factors Based on 4-Week Follow-up. Journal of Infection. 2020;80(6):629-45.

Qin L, Li X, Shi J, Yu M, Wang K, Tao Y, et al. Gendered effects on inflammation reaction and outcome of COVID-19 patients in Wuhan. Journal of Medical Virology. 2020;92(11):2684-92.

Mahmood M. Risk factors associated with mortality in COVID-19 patients : a retrospective case control study. 1-11.

Bonanad C, Blas SG, Santabalbina FT, et al. the effect of age on mortality in patients with COVID-19: A meta-analysis with 611,853 subjects. Journal of the American Medical Directors Association. 2020;21(7):915-8.

Noor FM, Islam MM. Prevalence and associated risk factors of mortality among COVID-19 patients: A meta-analysis. J Community Health. 2020;45(6):1270-82.

Sama IE, Ravera A, Santema BT, van Goor H, ter Maaten JM, Cleland JG, et al. Circulating plasma concentrations of ACE2 in men and women with heart failure and effects of renin-angiotensin-aldosteron-inhibitors. 2020;41(19):1810-7.

Pititto BDA, Dualib PM, Zajdenverg L, et al. Severity and mortality of COVID-19 in patients with diabetes, hypertension and cardiovascular disease: a meta-analysis. Diabetology & Metabolic Syndrome. 2020;12(1):75.

Singh AK, Gupta R, Ghosh A, Misra A. Diabetes in COVID-19: Prevalence, pathophysiology, prognosis and practical considerations. Diabetes & Metabolic Syndrome: Clinical Research & Review. 2020;14(4):303-310.

Liang X, Shi L, Wang Y, et al. the association of hypertension with the severity and mortality of COVID-19 patients: evidence based on adjusted effect estimates. J Infect. 2020;81(3):e44-47.

Chen L, Hao G. The role of angiotensin-converting enzyme 2 in corona viruses/influenza viruses and cardiovascular disease. Cardiovasc Res. 2020;0:1-5.

Zheng YY, Ma YT, Zhang JY, Xie X. COVID-19 and the cardiovascular system. Nat Rev Cardiol. 2002;17(5):259-60.

Xiong TY, Redwood S, Prendergast B, Chen M. Coronaviruses and the cardiovascular system: acute and long-term implications. Eur Heart J. 2020;41(19):1798-800.

Guan W, Liang W, Zhao Y, et al. Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis. Eur Respir J. 2020;2000547(14p).

Mehra MR, Desai SS, Kuy SR, Henry TD. Cardiovascular disease, drug therapy and mortality in COVID-19. N Engld J Med Jun. 2020;308:e102.

American Academy of Allergy Asthma & Immunology. An Update on COVID-19 for the Practicing Allergist/immunologist. 2021:1.

Rabb H. Kidney disease in the time of COVID-19 : Major Challenges to Patients Care. The Journal of Clinical Investigation. 2020;130(6):2749-51.

Cheng Y, Luo R, Wang K, Zhang M, Wang Z, Dong L, et al. Kidney disease is associated with in-hospital death of patients with COVID-19. 2020;97(5):829-38.

Williamson EJ, Walker EJ, Bhaskaran K, et al. Factors associated with COVID-19 related death. Nature. 2020;584(7821):430-6.

Benedetti C, Waldman M, Zaza G, Riella LV, Cravedi P. COVID-19 and the kidneys: an update. Front Med. 2020;7:1-13.

Ejaz H, Alsrhani A, Zafar A, Javed H, Junaid K, Abdalla AE, Abosalif KOA, Ahmed Z, Younas S, et al. COVID-19 and comorbidities: Deleterious impact on infected patients. Journal of Infection and Public Health. 2020;13(12):1833-1839.

D’Marco L, et al. Coronavirus disease 2019 in chronic kidney disease. Clinical Kidney Journal. 2020;13(3):297-306.